Diligence memo · auto-generated · as of July 2, 2026
Nephrx Corp
Nephrx Corp looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Nephrx Corp operates in Biotechnology, based in KALAMAZOO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nephrx Corp has raised $6.2M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.2M on 2007-11-15.
Most recent recorded round closed around 2007-11-15.
Valuation (modeled)modeled
Provath models Nephrx Corp at approximately $225M (range $6.8M–$1.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.76× the median modeled value of Series A Biotechnology companies in 2007–2009 (35 peers) — value vs value, same stage and era. Within the normal band (76% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 18.6 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 48% of Biotechnology peers (4293 compared).
Modeled value ranks above 73% of those peers.
Closest niche peers: Complete Genomics Inc, BioTrove, Inc., Aliva Biopharmaceuticals, LLC, Molecular Biometrics Inc, Bioimagene Inc.
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.